Author Archives: Lu Rahman

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine trial results: a watershed moment says immunology expert

The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis has shown. The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”. The analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Daniel Davis,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Pfizer and BioNTech vaccine COVID-19 candidate found to be more than 90% effective

Pfizer and BioNTech have announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antivirals #Cellular & Molecular biology #Drug targets

Sugar-coated viral proteins hijack and hitch a ride out of cells

Researchers from the Universities of Melbourne, York, Warwick and Oxford have shed light on how encapsulated viruses like hepatitis B, dengue and SARS-CoV-2 hijack the protein manufacturing and distribution pathways in the cell. They have also identified a potential broad spectrum anti-viral drug target to stop them in their tracks. Read More

#Editor's Choice #News

#Biotechnology #Drug discovery #Drug targets #Hit identification #Immunotherapy #Oncology

Partnership will progress targeted cancer immune therapy drug discovery

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an… Read More

#Cancer Research #News

#Clinical specialities #Clinical trials #HIV

Investigational injectable cabotegravir superior to oral care for female HIV prevention

ViiV Healthcare, the global specialist HIV company has announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of the HIV Prevention Trials Network (HPTN) 084 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention in women. Following a pre-specified interim analysis,… Read More

#News

#Drug development #Gene therapy

Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration

Oxford Biomedica, gene and cell therapy group and PhoreMost, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed. PhoreMost will deploy its in-house expertise and next-generation phenotypic… Read More

#Editor's Choice #News

#Drug development

Vary drug prices for different conditions, say health experts

According to a group of experts from across academia and industry, the NHS could improve patients’ access to new cancer treatments by paying different prices for drugs depending on the disease they are used to treat. The consensus panel, representing 16 leading academic institutions, charities, stakeholder groups and pharmaceutical companies,… Read More

#Editor's Choice #News

#Assay development & optimisation #Drug discovery

Putting the dynamics into compound profiling: using kinetic assays to shape early stage drug discovery

In vitro early stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay. However, in vivo, drug action occurs within a highly dynamic system. Drug and competing messenger… Read More

Webinar date:
Brought to you by SPT Labtech
#Webinars

#Covid-19 #CRISPR #High throughput screening

Mammoth Biosciences agreements to commercialise CRISPR-based SARS CoV-2 test

Mammoth Biosciences has signed agreements with MilliporeSigma and Hamilton Company targeting commercialisation of a high-throughput CRISPR-based SARS CoV-2 test. The test leverages Mammoth’s DETECTR BOOST platform and will provide a sample-to-answer turnkey solution for commercial laboratories to enable an increase in testing capacity. As laboratories face limited capacity and testing… Read More

#Covid-19 #News

#Cell therapy #Gene therapy

Digitalising cell and gene therapies manufacturing: a case study

Lonza will be hosting a free webinar to discuss its innovative approach to digitalising the company’s cell and gene therapy manufacturing operations through the implementation of the MODA-ESTM Platform. It will take place on 17 November. In the webinar, Lonza will also outline future plans for utilising the platform to… Read More

#News

#Biopharma #Drug development #Drug discovery

Thermo Fisher Scientific extends collaboration to advance biopharma discovery

Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody centre of excellence within the international pharmaceutical company, Servier, have extended a collaboration to deliver innovative characterisation and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development. Since the collaboration was… Read More

#News

#Covid-19 #CRISPR #Genetic editing

Stanford engineers develop a genetic microlab to detect COVID-19 in minutes

By Andrew Myers Throughout the pandemic, infectious disease experts and frontline medical workers have asked for a faster, cheaper and more reliable COVID-19 test. Now, leveraging the so-called “lab on a chip” technology and the cutting-edge genetic editing technique known as CRISPR, researchers at Stanford have created a highly automated… Read More

#Covid-19 #Editor's Choice #News

#Drug delivery

Researchers design tiny, star-shaped devices to deliver drugs more efficiently

Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body. David Gracias, a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins… Read More

#News

#Covid-19 #Drug repositioning

Beta-blockers could be used to treat COVID-19, says study

University of South Australia cancer researcher, Dr Nirmal Robinson, working with a team in Naples, has found evidence in animal models that the beta-blocker Propranolol helps suppress the spread of cancer in the lung which has an inflammatory profile very similar to COVID-19. The scientists have presented their findings in… Read More

#Covid-19 #News

#Exhibition #Neuroscience

SfN Global Connectome opens abstract submission

SfN Global Connectome will be a virtual event taking place on January 11–13 2021. This new digital neuroscience event is designed to allow scientific exchange across the globe and across the field, providing scientists at all career stages, of all disciplines, with opportunities to learn, collaborate, and connect. Highlights include:… Read More

#News